<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neth Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Neth Heart J</journal-id><journal-title-group><journal-title>Netherlands Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">1568-5888</issn><issn pub-type="epub">1876-6250</issn><publisher><publisher-name>Bohn Stafleu van Loghum</publisher-name><publisher-loc>Houten</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5260624</article-id><article-id pub-id-type="publisher-id">932</article-id><article-id pub-id-type="doi">10.1007/s12471-016-0932-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Early experience with the Venus p&#x02011;valve for percutaneous pulmonary valve implantation in native outflow tract</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Garay</surname><given-names>F.</given-names></name><address><email>fgaray@med.puc.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>X.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>YJ.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Springmuller</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution>Departamento de Cardiolog&#x000ed;a Pedi&#x000e1;trica y Enfermedades Respiratorias, Hospital Cl&#x000ed;nico de la Universidad Cat&#x000f3;lica de Chile, </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>Santiago Chile, Chile </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0368 8293</institution-id><institution-id institution-id-type="GRID">grid.16821.3c</institution-id><institution>Cardiovascular Department, Shanghai Chest Hospital, </institution><institution>Shanghai Jiao Tong University, </institution></institution-wrap>Shanghai, China </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2017</year></pub-date><volume>25</volume><issue>2</issue><fpage>76</fpage><lpage>81</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>The Venus p&#x02011;valve (MedTech, Shanghai, China) is a&#x000a0;self-expanding percutaneous heart valve designed to be implanted in a&#x000a0;native patched right ventricle outflow tract. The worldwide clinical experience with this valve is just beginning and the results have so far been encouraging. We present our initial early experience implanting the Venus p&#x02011;valve in the native right ventricle outflow tract of patients with Tetralogy of Fallot repaired with a&#x000a0;transannular patch.</p></sec><sec><title>Methods</title><p>In 10&#x000a0;selected patients a&#x000a0;procedure for percutaneous pulmonary valve implantation was performed using the Venus p&#x02011;valve. The patients mean age was 32&#x000a0;years (13&#x02013;57), mean weight 59.6&#x02009;kg (40&#x02013;80). All patients had Tetralogy of Fallot with moderate to severe pulmonary regurgitation and an indication for pulmonary valve replacement.</p></sec><sec><title>Results</title><p>The implantation procedure was successful in all the patients resulting in an immediately functional valve. No procedure-related complications were observed. Follow-up after 12&#x000a0;months (4&#x02013;21) resulted in an improvement in NYHA class. There was a&#x000a0;reduction of the mean right ventricle diastolic volume from 139&#x02009;ml/m<sup>2</sup> (105&#x02013;179) to 78&#x02009;ml/m<sup>2</sup> (65&#x02013;100) and improvement in the regurgitation fraction from 42% (29&#x02013;58) to 1% (0&#x02013;5), as seen on routine cardiac magnetic resonance 6&#x000a0;months after the implantation. No stent fractures have been observed so far.</p></sec><sec><title>Conclusion</title><p>Percutaneous pulmonary valve implantation with the Venus p&#x02011;valve resulted in a&#x000a0;safe and effective procedure. The valve has predictable and sustained functional competence, resulting in clinical improvement in the patients.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Pulmonary regurgitation</kwd><kwd>Percutaneous pulmonary valve implantation</kwd><kwd>Native right ventricle outflow tract</kwd><kwd>Venus p&#x02011;valve</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Percutaneous pulmonary valve implantation has become a&#x000a0;safe and effective option for patients needing pulmonary valve replacement after surgical repair [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. The currently available percutaneous valves (Melody or Sapien) are recommended to be implanted only in right ventricle outflow tracts (RVOT) constituted by homografts or conduits. However, most of the patients with Tetralogy of Fallot undergo a&#x000a0;repair using a&#x000a0;transannular patch technique which determines a&#x000a0;dilated and distensible RVOT usually exceeding the diameter of the available percutaneous valves [<xref ref-type="bibr" rid="CR4">4</xref>]. For these reasons there is a&#x000a0;need for a&#x000a0;valve that can be implanted in the native RVOT and is large enough for the diameters usually found in patched RVOT.</p><p>The Venus p&#x02011;valve (Venus MedTech, Shanghai, China) is a&#x000a0;self-expanding percutaneous valve designed to be implanted in a&#x000a0;native patched RVOT. It has already been tested [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] with satisfactory and encouraging results but is still not CE certified or FDA approved. The aim of this study was to report our initial experience on the feasibility and results of percutaneous implantation of the Venus P&#x02011;valve in the pulmonary position in patients with native RVOT.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p>Patients with Tetralogy of Fallot repaired using a&#x000a0;transannular patch technique were considered for percutaneous insertion of a&#x000a0;Venus p&#x02011;valve. Patients were selected based mostly on cardiac magnetic resonance (MRI) information when fulfilling two of the following inclusion criteria: moderate to severe pulmonary regurgitation and pulmonary regurgitant fraction &#x0003e;25%, right ventricular end-diastolic volume index &#x0003e;150&#x02009;ml/m<sup>2</sup>, right ventricular ejection fraction &#x0003c;45%, NYHA class&#x000a0;II or III symptoms and the pulmonary valve annulus or conduit size of &#x0003e;18&#x02009;mm and &#x0003c;30&#x02009;mm. Exclusion criteria were patients with body weight &#x0003c;30&#x02009;kg, occluded central veins, unfavourable RVOT anatomy as aneurysmal dilation, tortuosity of the main pulmonary artery (MPA) and a&#x000a0;pyramid-shaped RVOT.</p><p>All the patients were evaluated with transthoracic echocardiography to assess: right ventricular size and function, tricuspid regurgitation, right ventricular systolic pressure, RVOT gradient and the degree of pulmonary regurgitation. In particular, a&#x000a0;short axis view was used to measure the diameters of the pulmonary valve annulus, the MPA and pulmonary artery branches as well the MPA length, which is particularly useful for selecting the length of the valve to implant. MRI was also performed to define the size and the anatomy of the RVOT and pulmonary artery, left and right ventricular volumes and function and to calculate the pulmonary regurgitant fraction. With this information (particularly from echocardiographic measurements) the manufacturing company ensures that three or four possible valve sizes are available to be used in the patients on the day of the procedure. The study was approved by the local Institutional Review Board at each participating institution. Informed consent was obtained from the patients or parents for all the patients.</p></sec><sec id="Sec4"><title>Valve and delivery system</title><p>The Venus P&#x02011;valve consists of a&#x000a0;self-expanding stent made of nitinol with a&#x000a0;tri-leaflet porcine pericardial tissue valve preserved in a&#x000a0;low-concentration solution of buffered glutaraldehyde and hand-sewn inside of the nitinol frame (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The stent has proximal and distal flares to anchor the valve in the RVOT and in the pulmonary artery bifurcation. The proximal flare is covered by pericardial tissue, whereas the distal flare is an open cell wire frame to avoid obstruction of the pulmonary artery branches. The middle part is also fully covered by pericardium and the valve. There are three radiopaque platinum markers at the proximal flare to identify the valve location. The diameters of the middle part range from 18 to 34&#x02009;mm with 2&#x02009;mm increments and the lengths range from 20 to 35&#x02009;mm with 5&#x02009;mm increment. The proximal and distal flare diameters are 10&#x02009;mm larger than the middle segment. There are two small hooks at the proximal part of the valve for attachment to the delivery system (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The delivery system consists of a&#x000a0;16&#x02009;Fr 100-cm-long shaft catheter with a&#x000a0;20&#x02013;22&#x02009;Fr capsule and a&#x000a0;handle rotating mechanism for controlled deployment of the valve (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The valved stent is crimped and loaded onto the delivery system under sterile cold saline solution which helps to reduce the memory property of nitinol. The delivery system is advanced through a&#x000a0;22&#x02013;24&#x02009;Fr sheath.<fig id="Fig1"><label>Fig. 1</label><caption><p>The Venus p&#x02011;valve. Note its particular design with flared ends, the non-covered distal end and the proximal hooks or &#x02018;ears&#x02019; for attaching mechanism to the delivery catheter</p></caption><graphic xlink:href="12471_2016_932_Fig1_HTML" id="d29e290"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>The Venus p&#x02011;valve delivery system. Note the handle with a&#x000a0;knob for slow and controlled release of the valve and the distal capsule with a&#x000a0;crimped and loaded valve inside. The <italic>arrow</italic> signs a&#x000a0;distal radiopaque mark</p></caption><graphic xlink:href="12471_2016_932_Fig2_HTML" id="d29e303"/></fig>
</p></sec><sec id="Sec5"><title>Procedure</title><p>All procedures were performed under general anaesthesia and biplane laboratory was used. Anticoagulation with heparin 100 UI/kg was routinely used at the beginning of the procedure. Intraprocedural cefazolin 100&#x02009;mg/kg/day was given. Following a&#x000a0;full basic haemodynamic assessment, angiograms were performed in the RVOT and MPA in order to characterise the shape and diameter of the RVOT and pulmonary artery bifurcation. Angiograms were usually performed in posteroanterior and lateral projections, and additionally in right anterior oblique with cranial angulation or left anterior oblique with cranial angulation for a&#x000a0;better visualisation of the pulmonary artery bifurcation, since this understanding is key for the valve deployment. The coronary artery occlusion test was routinely performed with an aortic angiogram or selective left coronary angiography simultaneously with inflation of a&#x000a0;34&#x02009;mm Amplatzer sizing balloon in the MPA to assess the expansibility and diameters as well as the proximity or compression of the left coronary artery (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) which contraindicates the procedure.<fig id="Fig3"><label>Fig. 3</label><caption><p>Sizing balloon interrogation of the right ventricle outflow tract in caudal projection (<bold>a</bold>) and lateral projection (<bold>b</bold>) with measurements included. Simultaneously selective left coronary angiogram is observed</p></caption><graphic xlink:href="12471_2016_932_Fig3_HTML" id="d29e327"/></fig>
</p><p>The selection of the valve size and length to implant was based on the minimum diameter of the pulmonary valve annulus/MPA during the sizing interrogation, selecting a&#x000a0;valve diameter 3&#x02013;4&#x02009;mm larger than any waist in the sizing balloon. The valve length was selected to cover but not exceed the MPA length measured from the pulmonary valve annulus to the pulmonary artery bifurcation on transthoracic echocardiograph. Once the valve was prepared and loaded into the delivery catheter, it was advanced over an extra-stiff wire (260-cm, 0.035&#x02032; Lunderquist, Cook Medical) located distal in the left pulmonary artery. The valve was advanced into the main pulmonary artery observing the distal radiopaque markers of the valve being positioned just before the pulmonary artery bifurcation (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Then a&#x000a0;slow and controlled valve deployment is performed by clockwise rotation of the knob in the handle. Repeated RVOT angiography is performed during the delivery to ensure an optimal position and that the distal end is not jailing any of the pulmonary artery branches. After valve deployment, evaluation is immediately performed including haemodynamic assessment, pulmonary artery angiography and transthoracic echocardiography. Haemostasis could be achieved by using a&#x000a0;figure-of-eight suture, preclosure with the Abbott Perclose Proglide device or manual compression according operator preferences.<fig id="Fig4"><label>Fig. 4</label><caption><p>Fluoroscopic images demonstrating several steps of the implantation procedure. Basal angiogram in the main pulmonary artery in LAO and cranial projection to visualise pulmonary artery bifurcation (<bold>a</bold>), advancing and positioning Venus p&#x02011;valve delivery system in the RVOT with the tip advanced into proximal left branch (<bold>b</bold>), deployment of the distal end of the valve (<bold>c</bold>), deployment of the central part of the valve (<bold>d</bold>), Venus p&#x02011;valve completely deployed in an appropriate position (<bold>e</bold>) and final angiogram demonstrating a&#x000a0;functional valve and patent pulmonary branches (<bold>f</bold>)</p></caption><graphic xlink:href="12471_2016_932_Fig4_HTML" id="d29e361"/></fig>
</p></sec><sec id="Sec6"><title>Statistics</title><p>Continuous variables are expressed as means, whereas categorical variables are presented as numbers. Comparison of parameters before and after pulmonary valve implantation was analysed using Wilcoxon&#x02019;s signed rank test. A&#x000a0;<italic>p</italic>-value &#x0003c;0.05 was considered to be statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><p>Ten patients (7&#x000a0;female) were selected to receive a&#x000a0;Venus p&#x02011;valve and it was successfully implanted in all of them. Their mean age was 32&#x000a0;years (range 13&#x02013;57) and their mean weight was 59.6&#x02009;kg (range 40&#x02013;80) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Functional class was NYHA&#x000a0;II in 7&#x000a0;patients and NYHA&#x000a0;III in 3&#x000a0;patients. All the patients had a&#x000a0;basal cardiac MRI that showed a&#x000a0;pulmonary valve annulus with a&#x000a0;median of 22.7&#x02009;mm (range 18 and 27&#x02009;mm). The mean pulmonary regurgitant fraction was 42% (range 29&#x02013;58%), mean right ventricular ejection fraction was 50.9% (range 33&#x02013;81%) and mean right ventricular end-diastolic volume index was 139&#x02009;ml/m<sup>2</sup> (range 105&#x02013;179&#x02009;ml/m<sup>2</sup>). The mean MPA diameter measured by sizing balloon interrogation was 27&#x02009;mm (range 21&#x02013;30&#x02009;mm). The mean length of the MPA was 28.1&#x02009;mm&#x000a0;&#x000b1; 6.5&#x02009;mm (range 21 to 38&#x02009;mm). The implanted valve diameters ranged from 26 to 32&#x02009;mm, whereas the selected implanted valve length was 25&#x02009;mm in 7 and 30&#x02009;mm in 3&#x000a0;patients. Immediate angiography in the MPA after valve implantation revealed a&#x000a0;competent valve in all the patients. The mean diastolic pulmonary artery pressure increased from 11.4 to 18.9&#x02009;mm&#x02009;Hg demonstrating a&#x000a0;functional valve (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The pressure gradient across the RVOT decreased from 10.3&#x02009;mm&#x02009;Hg (range 0&#x02013;30) to 2.9&#x02009;mm&#x02009;Hg (range 0&#x02013;10) after the procedure. The mean fluoroscopy was 29&#x02009;min (range 23.7&#x02013;35). The radiation dose had a&#x000a0;mean dose area product of 19,880&#x02009;mGy*m<sup>2</sup> (range 5317&#x02013;23,454&#x02009;mGy*m<sup>2</sup>) and a&#x000a0;mean total air Kerma of 1598&#x02009;mGy (range 218&#x02013;2233&#x02009;mGy). There were no procedure-related complications and no evidence of paravalvular leaks in any of the patients on transthoracic echocardiogram immediately after the procedure. The large profile of the delivery system did not result in any obvious vascular damage, nor did it prevent the advance of the valve through heart structures.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of the patients: demographics and preprocedural measurements</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Age<break/>(years)</th><th>Weight<break/>(kg)</th><th>Height<break/>(cm)</th><th>Sex</th><th>Diagnosis</th><th>MPA<break/>diameter echo<break/>(mm)</th><th>MPA<break/>diameter<break/>MRI<break/>(mm)</th><th>MPA<break/>diameter<break/>sizing<break/>(mm)</th><th>MPA length<break/>echo<break/>(mm)</th><th>Diameter<break/>implanted<break/>Venus valve<break/>(mm)</th><th>Length<break/>implanted<break/>Venus valve<break/>(mm)</th></tr></thead><tbody><tr><td>1</td><td>13</td><td>59</td><td>157</td><td>M</td><td>TOF</td><td>28</td><td>23</td><td>27</td><td>35</td><td>30</td><td>30</td></tr><tr><td>2</td><td>15</td><td>53</td><td>151</td><td>F</td><td>TOF</td><td>24</td><td>23</td><td>28</td><td>32</td><td>26</td><td>25</td></tr><tr><td>3</td><td>13</td><td>67</td><td>162</td><td>F</td><td>TOF</td><td>28</td><td>27</td><td>30</td><td>36</td><td>30</td><td>30</td></tr><tr><td>4</td><td>25</td><td>52</td><td>162</td><td>F</td><td>TOF</td><td>28</td><td>26</td><td>29</td><td>22</td><td>32</td><td>25</td></tr><tr><td>5</td><td>15</td><td>40</td><td>165</td><td>F</td><td>TOF</td><td>26</td><td>25</td><td>27</td><td>23</td><td>30</td><td>25</td></tr><tr><td>6</td><td>50</td><td>51</td><td>152</td><td>F</td><td>PVS</td><td>24</td><td>22</td><td>26</td><td>21</td><td>28</td><td>25</td></tr><tr><td>7</td><td>57</td><td>80</td><td>165</td><td>F</td><td>TOF</td><td>25</td><td>18</td><td>28</td><td>27</td><td>28</td><td>30</td></tr><tr><td>8</td><td>44</td><td>72</td><td>168</td><td>M</td><td>TOF</td><td>29</td><td>23</td><td>30</td><td>24</td><td>32</td><td>25</td></tr><tr><td>9</td><td>39</td><td>68</td><td>175</td><td>M</td><td>PVS</td><td>27</td><td>22</td><td>21</td><td>38</td><td>26</td><td>25</td></tr><tr><td>10</td><td>49</td><td>54</td><td>158</td><td>F</td><td>TOF</td><td>20</td><td>18</td><td>24</td><td>23</td><td>26</td><td>25</td></tr><tr><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>Mean</td><td>32</td><td>59.6</td><td>161.5</td><td>&#x02013;</td><td>&#x02013;</td><td>25.9</td><td>22.7</td><td>27</td><td>28</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><p>
<italic>TOF</italic>&#x000a0;Tetralogy of Fallot, <italic>PVS</italic>&#x000a0;pulmonary valve stenosis, <italic>MPA</italic>&#x000a0;main pulmonary artery, <italic>RV</italic>&#x000a0;right ventricle, <italic>PA</italic>&#x000a0;pulmonary artery</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of the patients: haemodynamics and MRI information</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Basal RV-PA gradient<break/>(mm&#x02009;Hg)</th><th>Post RV-PA gradient<break/>(mm&#x02009;Hg)</th><th>Basal diastolic PA pressure<break/>(mm&#x02009;Hg)</th><th>Post diastolic PA pressure<break/>(mm&#x02009;Hg)</th><th>Basal RVDV<break/>(ml/m<sup>2</sup>)</th><th>Post RVDV<break/>(ml/m<sup>2</sup>)</th><th>Basal pulmonary regurgitation fraction<break/>(%)</th><th>Post pulmonary regurgitation fraction<break/>(%)</th></tr></thead><tbody><tr><td>1</td><td>5</td><td>4</td><td>12</td><td>15</td><td>142</td><td>
<sup>a</sup>
</td><td>44</td><td>
<sup>a</sup>
</td></tr><tr><td>2</td><td>8</td><td>7</td><td>9</td><td>16</td><td>151</td><td>
<sup>a</sup>
</td><td>29</td><td>
<sup>a</sup>
</td></tr><tr><td>3</td><td>9</td><td>0</td><td>9</td><td>12</td><td>179</td><td>
<sup>a</sup>
</td><td>58</td><td>
<sup>a</sup>
</td></tr><tr><td>4</td><td>11</td><td>0</td><td>17</td><td>18</td><td>105</td><td>66</td><td>30</td><td>0</td></tr><tr><td>5</td><td>15</td><td>3</td><td>10</td><td>20</td><td>131</td><td>100</td><td>41</td><td>0</td></tr><tr><td>6</td><td>5</td><td>0</td><td>11</td><td>14</td><td>113</td><td>90</td><td>33</td><td>0</td></tr><tr><td>7</td><td>15</td><td>10</td><td>13</td><td>37</td><td>
<sup>a</sup>
</td><td>
<sup>a</sup>
</td><td>
<sup>a</sup>
</td><td>
<sup>a</sup>
</td></tr><tr><td>8</td><td>5</td><td>0</td><td>10</td><td>18</td><td>155</td><td>73</td><td>58</td><td>0</td></tr><tr><td>9</td><td>30</td><td>5</td><td>10</td><td>14</td><td>147</td><td>70</td><td>49</td><td>0</td></tr><tr><td>10</td><td>0</td><td>0</td><td>13</td><td>25</td><td>131</td><td>72</td><td>39</td><td>5</td></tr><tr><td>Mean</td><td>10.3</td><td>2.9</td><td>11.4</td><td>18.9</td><td>139</td><td>78*</td><td>42</td><td>1*</td></tr></tbody></table><table-wrap-foot><p>
<italic>RV</italic>&#x000a0;right ventricle, <italic>PA</italic>&#x000a0;pulmonary artery, <italic>RVDV</italic>&#x000a0;right ventricle diastolic volume</p><p>*<italic>p</italic>&#x000a0;&#x02264; 0.05</p><p>
<sup>a</sup>data not available</p></table-wrap-foot></table-wrap>
</p><p>During a&#x000a0;mean follow-up of 12&#x000a0;months (range 4&#x02013;21) all the patients have remained in NYHA functional class&#x000a0;I. Transthoracic echocardiography and MRI 6&#x000a0;months after implantation of the valve showed sustained and significant reduction of the pulmonary regurgitation in all the patients (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In 6&#x000a0;patients with MRI follow-up the median pulmonary regurgitant fraction was 1% (range 0&#x02013;5%; significant at <italic>p</italic>&#x000a0;&#x02264; 0.05) and the right ventricular end-diastolic volume index was 78&#x02009;ml/m<sup>2</sup> (range 66&#x02013;100&#x02009;ml/m<sup>2</sup>; significant at <italic>p</italic>&#x000a0;&#x02264; 0.05). No stent fracture was demonstrated on fluoroscopic follow-up at 6&#x000a0;months.</p></sec><sec id="Sec8"><title>Discussion</title><p>The worldwide experience in implanting the Venus p&#x02011;valve is just beginning with as yet few published reports. We have reproduced the encouraging results reported by Cao and Prompham in 11&#x000a0;patients with Tetralogy of Fallot repaired using the transannular patch technique [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. We report an additional 10 patients with satisfactory results and have demonstrated a&#x000a0;significant reduction of the right ventricular end-diastolic volume index and sustainable valve integrity on follow-up MRI. These results are similar to the early results with Melody and Sapien systems [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Before the currently available percutaneous pulmonary valves (Melody and Sapien) can be used in a&#x000a0;native RVOT it is necessary to first implant a&#x000a0;large stent to transform the native RVOT into a&#x000a0;rigid conduit [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. For a&#x000a0;native RVOT up to 26&#x02013;27&#x02009;mm, pre-stenting followed by implantation of any of these valves can be performed during the same procedure or in a&#x000a0;staged approach. Also an RVOT reducer used with a&#x000a0;self-expanding valve has been previously reported to address this problem, but it has not resulted in any development [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The Venus p&#x02011;valve appears to be an option to address this scenario. This valve is currently available up to a&#x000a0;maximum diameter of 34&#x02009;mm, which is indicated for RVOT up to 30&#x02013;32&#x02009;mm. Prompham reported that 6 of 16&#x000a0;patients with the native RVOT and indication for pulmonary valve replacement could be selected to receive a&#x000a0;Venus p&#x02011;valve [<xref ref-type="bibr" rid="CR6">6</xref>]. Patients were excluded because of a&#x000a0;severely dilated main pulmonary artery or unfavourable RVOT anatomy, such as short pyramid shaped RVOT. Selection of our patients based on MRI and echocardiographic measurements was effective since all of them underwent a&#x000a0;successful procedure.</p><p>During the procedure, the deployment and positioning of the distal end of the valve must to be very precise so that it does not excessively protrude into the pulmonary artery bifurcation. To achieve this, radiopaque marks on the distal end of the straight part of the valve have to be positioned just at the pulmonary artery bifurcation. Repeated RVOT angiograms are used to help with this fine positioning. Some of these angiograms can be avoided when using 3DRA guidance and on screen 3D roadmap [<xref ref-type="bibr" rid="CR11">11</xref>]. Haemodynamic monitoring is crucial during the deployment because this is a&#x000a0;covered stent and when the valve is half deployed the blood flow through the RVOT can be compromised resulting in hypotension or bradycardia. The proximal end of the valve needs to be quickly deployed which results in a&#x000a0;rapid recovery of haemodynamics and rhythm.</p><p>Incomplete detachment of the valve has been reported causing unintentional valve migration into the right ventricle [<xref ref-type="bibr" rid="CR6">6</xref>]. In order to avoid this, attention must to be paid to the appearance of the proximal flare in two different fluoroscopic views checking the release from the proximal hooks. If one of these is not fully released gentle clockwise or counterclockwise rotation of the delivery system may allow the hooks to detach completely from the delivery system. Also, as a&#x000a0;safety tip, the distal end (&#x02018;carrot&#x02019;) of the delivery catheter must be pulled back carefully and under fluoroscopic imaging to rule out the theoretical risk of engaging the stent with this.</p><p>Stent fractures were not seen in our patients. This has been reported for the Melody valve and pre-stenting has reduced this [<xref ref-type="bibr" rid="CR12">12</xref>]. For Venus p&#x02011;valve implantation, pre-stenting is not necessary but it is possible that a&#x000a0;dilated non-calcified native RVOT exerts less compression force on the stent frame avoiding the occurrence of stent fractures. However, the proximal end of the Venus valve is deployed in the contractile RVOT, this being a&#x000a0;factor to produce stent fractures. Follow-up studies will be needed to evaluate the occurrence of late fractures.</p></sec><sec id="Sec9"><title>Conclusions</title><p>Our experience reproduces the encouraging initial results of implanting the Venus p&#x02011;valve in patients with Tetralogy of Fallot repaired using the transannular patch technique. The Venus p&#x02011;valve is expanding the scope of percutaneous valve implantation in patients with a&#x000a0;dilated RVOT which is out of range for the available percutaneous valves. The Venus p&#x02011;valve seems to work well in the short term follow-up. Further long-term studies are needed to bring more information on issues like durability and fractures.</p></sec></body><back><ack><sec id="FPar1"><title>Acknowledgements</title><p>This work was supported by Venus MedTech (Shangai, China) who donated the valves that were implanted in the reported series.</p></sec></ack><notes notes-type="COI-statement"><sec id="FPar2"><title>Conflict of interest</title><p>F. Garay and X.&#x000a0;Pan are consultants for Venus MedTech. YJ.&#x000a0;Zhang, C.&#x000a0;Wang and D.&#x000a0;Springmuller declare that they have no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElhinney</surname><given-names>DB</given-names></name><name><surname>Hellenbrand</surname><given-names>WE</given-names></name><name><surname>Zahm</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.921692</pub-id><?supplied-pmid 20644013?><pub-id pub-id-type="pmid">20644013</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>D</given-names></name><name><surname>Hijazi</surname><given-names>ZM</given-names></name><name><surname>Kar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>21</volume><fpage>2248</fpage><lpage>2256</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.07.040</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faza</surname><given-names>N</given-names></name><name><surname>Kenny</surname><given-names>D</given-names></name><name><surname>Kavinsky</surname><given-names>C</given-names></name><name><surname>Amin</surname><given-names>Z</given-names></name><name><surname>Heitschmidt</surname><given-names>M</given-names></name><name><surname>Hijazi</surname><given-names>ZM</given-names></name></person-group><article-title>Single-center comparative outcomes of the Edwards SAPIEN and medtronic melody transcatheter heart valves in the pulmonary position</article-title><source>Catheter Cardiovasc Interv</source><year>2013</year><volume>82</volume><fpage>E535</fpage><lpage>E541</lpage><?supplied-pmid 23008193?><pub-id pub-id-type="pmid">23008193</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schievano</surname><given-names>S</given-names></name><name><surname>Coats</surname><given-names>L</given-names></name><name><surname>Migliavacca</surname><given-names>F</given-names></name><etal/></person-group><article-title>Variations in right ventricular outflow tract morphology following repair of congenital heart disease: implications for percutaneous pulmonary valve implantation</article-title><source>J Cardiovasc Magn Reson</source><year>2007</year><volume>9</volume><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1080/10976640601187596</pub-id><?supplied-pmid 17578725?><pub-id pub-id-type="pmid">17578725</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>QL</given-names></name><name><surname>Kenny</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><etal/></person-group><article-title>Early clinical experience with a&#x000a0;novel self-expanding percutaneous stent-valve in the native right ventricular outflow tract</article-title><source>Catheter Cardiovasc Interv</source><year>2014</year><volume>84</volume><fpage>1131</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1002/ccd.25544</pub-id><?supplied-pmid 24824357?><pub-id pub-id-type="pmid">24824357</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Promphan</surname><given-names>W</given-names></name><name><surname>Prachasilchai</surname><given-names>P</given-names></name><name><surname>Siripornpitak</surname><given-names>S</given-names></name><name><surname>Qureshi</surname><given-names>SA</given-names></name><name><surname>Layangool</surname><given-names>T</given-names></name></person-group><article-title>Percutaneous pulmonary valve implantation with the Venus P&#x02011;valve: clinical experience and early results</article-title><source>Cardiol Young</source><year>2016</year><volume>26</volume><fpage>698</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1017/S1047951115001067</pub-id><?supplied-pmid 26088820?><pub-id pub-id-type="pmid">26088820</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>DS</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Salem</surname><given-names>MM</given-names></name><name><surname>Aboulhosn</surname><given-names>JA</given-names></name></person-group><article-title>Transcatheter native pulmonary valve and tricuspid valve replacement with the sapien XT: initial experience and development of a&#x000a0;new delivery platform</article-title><source>Catheter Cardiovasc Interv</source><year>2016</year></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meadows</surname><given-names>JJ</given-names></name><name><surname>Moore</surname><given-names>PM</given-names></name><name><surname>Berman</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Use and performance of the melody transcatheter pulmonary valve in native and postsurgical, nonconduit right ventricular outflow tracts</article-title><source>Circ Cardiovasc Interv</source><year>2014</year><volume>7</volume><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.114.001225</pub-id><?supplied-pmid 24867892?><pub-id pub-id-type="pmid">24867892</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudjemline</surname><given-names>Y</given-names></name><name><surname>Agnoletti</surname><given-names>G</given-names></name><name><surname>Bonnet</surname><given-names>D</given-names></name><name><surname>Sidi</surname><given-names>D</given-names></name><name><surname>Bonhoeffer</surname><given-names>P</given-names></name></person-group><article-title>Percutaneous pulmonary valve replacement in a&#x000a0;large right ventricular outflow tract: an experimental study</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><fpage>1082</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2003.10.037</pub-id><?supplied-pmid 15028370?><pub-id pub-id-type="pmid">15028370</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schievano</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>AM</given-names></name><name><surname>Capelli</surname><given-names>C</given-names></name><etal/></person-group><article-title>First-in-man implantation of a&#x000a0;novel percutaneous valve: a&#x000a0;new approach to medical device development</article-title><source>EuroIntervention</source><year>2010</year><volume>5</volume><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.4244/EIJV5I6A122</pub-id><?supplied-pmid 20142228?><pub-id pub-id-type="pmid">20142228</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagan</surname><given-names>T</given-names></name><name><surname>Kay</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>J</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name></person-group><article-title>3-D guidance of complex pulmonary artery stent placement using reconstructed rotational angiography with live overlay</article-title><source>Catheter Cardiovasc Interv</source><year>2012</year><volume>79</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1002/ccd.23229</pub-id><?supplied-pmid 21735535?><pub-id pub-id-type="pmid">21735535</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElhinney</surname><given-names>DB</given-names></name><name><surname>Cheatham</surname><given-names>JP</given-names></name><name><surname>Jones</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient related and procedural risk factors in the US melody valve trial</article-title><source>Circ Cardiovasc Interv</source><year>2011</year><volume>6</volume><fpage>602</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.111.965616</pub-id></element-citation></ref></ref-list></back></article>